2022 Norton Education Series: Irritable Bowel Syndrome Event
Resident Sponsor: Ardelyx

ardelyx

“Here at Ardelyx®, we are dedicated to improving the lives of patients by discovering, developing and commercializing first-in-class targeted therapies that advance patient care. Using our discovery model, Ardelyx scientists identified new biological mechanisms and pathways that enabled us to develop drug candidates designed to address significant unmet medical needs with the goal of improving outcomes for patients.”

Share this page
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
Topics of this article
Was this article helpful?

IFFGD is a nonprofit education and research organization. Our mission is to inform, assist, and support people affected by gastrointestinal disorders.

Our original content is authored specifically for IFFGD readers, in response to your questions and concerns.

If you found this article helpful, please consider supporting IFFGD with a small tax-deductible donation.

Related Information
Personal Stories
Skip to content